Essential oils as capsule disruptors: enhancing antibiotic efficacy against multidrug-resistant Klebsiella pneumoniae
Frontiers in Microbiology · 30.08.2024 · 15
DOI: 10.3389/fmicb.2024.1467460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 30.08.2024. Verfasst von Azza SalahEldin El-Demerdash und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biotechnology, Department of Microbiology, Agricultural Research Center (ARC), Animal Health Research Institute (AHRI), Zagazig, Egypt. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Multidrug-resistant Klebsiella pneumoniae (MDR- KP ) poses a significant global health threat due to its involvement in severe infections and high mortality rates. The emergence of MDR strains necessitates the exploration of alternative therapeutic strategies.
Methods
K. pneumoniae isolates were obtained from human and animal sources. Antibacterial susceptibility testing was performed, followed by the evaluation of essential oil activity through inhibition zone, MIC, and MBC determinations. Checkerboard assays were conducted to assess synergistic effects with amikacin. Gene expression analysis and transmission electron microscopy were employed to elucidate the mechanisms of action. Molecular docking studies were performed to identify potential binding targets of bioactive compounds.
Results
Klebsiella pneumoniae was isolated from 25 of the100 samples examined, representing a prevalence rate of 25%. All isolates were found to be multidrug-resistant. Tea tree and thyme essential oils exhibited potent antibacterial activity and synergistic effects with amikacin. Notably, these combinations significantly downregulated the expression of key capsule virulence genes ( wcaG , rmpA , magA , uge , and wabG ), suggesting a novel mechanism for enhancing amikacin efficacy. Transmission electron microscopy revealed disrupted cell integrity in MDR-KP cells treated with the combinations. Molecular docking analysis identified Terpinen-4-ol, Farnesol, 1,4-Dihydroxy-p-menth-2-ene, and 7-Oxabicyclo [4.1.0] heptane as potential bioactive compounds responsible for the observed effects.
Conclusion
By effectively combating MDR-KP, this research holds promise for reducing antibiotic resistance, improving treatment outcomes, and ultimately enhancing potential care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Biotechnology, Department of Microbiology, Agricultural Research Center (ARC), Animal Health Research Institute (AHRI), Zagazig, Egypt.
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- Botany and Microbiology Department, Faculty of Science, Benha University, Benha, Egypt.
- Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
- Epidemiological Surveillance Unit, Aweash El-Hagar Family Medicine Center, MOHP, Mansoura, Egypt.
Zitieren
APA
El-Demerdash, A. S., Alfaraj, R., Farid, F. A., Yassin, M. H., Saleh, A. M., & Dawwam, G. E. (2024). Essential oils as capsule disruptors: enhancing antibiotic efficacy against multidrug-resistant Klebsiella pneumoniae. Frontiers in Microbiology, 15. https://doi.org/10.3389/fmicb.2024.1467460
Vancouver
El-Demerdash AS, Alfaraj R, Farid FA, Yassin MH, Saleh AM, Dawwam GE. Essential oils as capsule disruptors: enhancing antibiotic efficacy against multidrug-resistant Klebsiella pneumoniae. Frontiers in Microbiology. 2024;15. doi:10.3389/fmicb.2024.1467460
BibTeX
@article{ElDemerdash2024,
author = {El-Demerdash, Azza SalahEldin and Alfaraj, Rihaf and Farid, Faten A and Yassin, Mohamed H and Saleh, Abdulrahman M and Dawwam, Ghada E},
title = {Essential oils as capsule disruptors: enhancing antibiotic efficacy against multidrug-resistant Klebsiella pneumoniae},
journal = {Frontiers in Microbiology},
year = {2024},
volume = {15},
doi = {10.3389/fmicb.2024.1467460}
}
EUVIMED